SLC5A2 and type 2 diabetes mellitus: Medications, TDZs [148], GLP-1RAs [150], and SGLT2 antagonists, control hyperglycemia, lower HbA1C [157], and improve T2DM and cardiovascular issues, favorable alteration of serum lipid profile, and additionally fatty degeneration of the liver.